SLS News and Press, SELLAS Life Sciences Group Inc.

- Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children – - Rare Pediatric Disease Designation (RPDD) Provides Eligibility for SLS009 to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – ...

2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...

2024-06-17 15:07:56 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout Solaris Resources announces $35 million bought deal offering Sellas reports positive Phase 2 data from AML study, files for patent See...

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...

2024-06-17 09:45:40 ET Palm Beach, FL – June 17, 2024 – According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the...

– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – – No Safety or Futility Concerns Were Raised Based on the Efficacy and Safety Assessment of All REGAL Patients – ...

- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts, Respectively - - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Su...

2024-05-21 17:42:10 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout Sellas reports positive Phase 2 data from AML study, files for patent SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL...

2024-05-14 16:58:41 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout Sellas reports positive Phase 2 data from AML study, files for patent SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL...

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...